Regulation of Self-Care Products in Canada
https://policybase.cma.ca/link/policy13802

POLICY TYPE  Response to consultation
DATE  2016-10-31
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
Statement to the House of Commons Committee on Health addressing the opioid crisis in Canada
https://policybase.cma.ca/link/policy13936

POLICY TYPE: Parliamentary submission
DATE: 2016-10-18
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health
Health care and patient safety

Documents
Legalization, regulation and restriction of access to marijuana
https://policybase.cma.ca/link/policy11954

POLICY TYPE  Response to consultation
DATE  2016-08-29
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission
Legalization, Regulation and Restriction of Access to Marijuana

Government of Canada – Task Force on Marijuana Legalization and Regulation

August 29, 2016

STATEMENT  DIÉLATION

Chief Statement: Application of Evidence

Evidence, September 1, 2016 - The CMA’s submission to the Task Force on Marijuana Legalization and Regulation and its recommendations are based on evidence from the scientific literature, established best practices and international data.

We must move with urgency to meet the health needs of Canadians. Marijuana use is a serious public health concern and requires urgent action.

The dual-track approach to legalization by the federal government is flawed. A second class of exposure, health and safety risks to Canadians’ health and safety will be exposed.

As a matter of public health, the CMA’s recommendations should be considered recommendations for the Health Canada’s plain and standard packaging legislation from CMA’s experience in the United States.

We recommend:

1. A comprehensive, evidence-based approach to legalizing marijuana
2. Establishing a system that promotes public health
3. Implementing strong post-marketing surveillance systems
4. Monitoring and analyzing the health effects of marijuana use

We are concerned that the current proposal is not comprehensive and does not meet the needs of Canadians.

We support the following recommendations from CMA’s experience in the United States:

- Promoting public health
- Establishing a system that promotes public health
- Implementing strong post-marketing surveillance systems
- Monitoring and analyzing the health effects of marijuana use

We urge government to consider these recommendations in its legislation.

For information, contact: 1-888-619-6736
Health Canada’s Consultation on “Plain and Standardized Packaging”
https://policybase.cma.ca/link/policy13817

POLICY TYPE
Response to consultation

DATE
2016-08-12

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
National pharmacare in Canada: Getting there from here

https://policybase.cma.ca/link/policy11959

POLICY TYPE  Parliamentary submission
DATE  2016-06-01
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission
National Pharmacare in Canada: Getting There from Here

Submission to the House of Commons Standing Committee on Health
June 1 2016
Consultation on the prescription drug list: Naloxone
https://policybase.cma.ca/link/policy11847

POLICY TYPE
Response to consultation

DATE
2016-03-19

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Regulatory framework for the mandatory reporting of adverse drug reactions and medical device incidents by provincial and territorial healthcare institutions.

https://policybase.cma.ca/link/policy11814

POLICY TYPE Response to consultation
DATE 2016-01-20
TOPICS Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents